DIPG DMG National Brain Tumor Board
Offering treating providers of Diffuse Midline Gliomas, including Diffuse Intrinsic Pontine Gliomas, patient centered advice on innovative treatment options and clinical trials.
To be evaluated for the DIPG DMG National Brain Tumor Board, please complete the following information. Our coordinator will contact the patient provider within three business days of submittal.
What is the DIPG DMG National Brain Tumor Board?
- FREE AND CONFIDENTIAL
- PROVIDER RESOURCE FOR TREATMENT IN THE US
- GUIDANCE FOR TREATMENT OF DIPG DMG PATIENTS
ADAM GREEN,
MD PEDIATRIC NEURO ONCOLOGY
MD PEDIATRIC NEURO ONCOLOGY
CHILDREN’S
HOSPITAL OF COLORADO
ASHLEY PLANT-FOX, MD
PEDIATRIC NEURO ONCOLOGY
LURIE CHILDREN’S
HOSPITAL
HOSPITAL
CARL KOSCHMANN, MD
PEDIATRIC NEURO ONCOLOGY
C.S. MOTT CHILDREN’S HOSPITAL
CHENG-CHIA WU,
MD, PhD PEDIATRIC NEURO ONCOLOGY
MD, PhD PEDIATRIC NEURO ONCOLOGY
COLUMBIA UNIVERSITY IRVING MEDICAL CENTER
DAVID MIRSKY, MD
PEDIATRIC NEURORADIOLOGIST
CHILDREN’S HOSPITAL COLORADO
GERALD A. GRANT, MD
NEUROSURGEON
DUKE
HEALTH SYSTEMS
HEALTH SYSTEMS
JASON FANGUSARO, MD
PEDIATRIC NEURO ONCOLOGY
CHILDREN’S HEALTHCARE OF ATLANTA
LINDSAY KILBURN, MD
PEDIATRIC NEURO ONCOLOGY
CHILDREN’S NATIONAL HOSPITAL
MATTHEW BARKOVICH, MD
NEURORADIOLOGIST
UCSF BENIOFF CHILDREN'S HOSPITAL
MICHELLE MONJE, MD, PhD
PEDIATRIC NEURO ONCOLOGY
LUCILE PACKARD CHILDREN’S HOSPITAL
NALIN GUPTA, MD, PhD
NEUROSURGEON
UCSF BENIOFF CHILDREN’S HOSPITAL
NICHOLAS VITANZA, MD
PEDIATRIC NEURO ONCOLOGY
SEATTLE CHILDREN’S HOSPITAL
PATRICIA BAXTER, MD, MBA
PEDIATRIC NEURO ONCOLOGY
TEXAS CHILDREN’S
HOSPITAL
HOSPITAL
REBECCA RONSLEY, MD, FRCPC
PEDIATRIC NEURO ONCOLOGY
SEATTLE CHILDREN'S HOSPITAL
SABINE MUELLER, MD, PhD
PEDIATRIC NEURO ONCOLOGY
UCSF BENIOFF CHILDREN’S HOSPITAL
SEBASTIAN WASZAK, PhD
PEDIATRIC NEURO ONCOLOGY
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (UCSF)
The DIPG DMG National Brain Tumor Board also consults with the following when needed to complete its review:
Gerald Grant, MD, Neurosurgeon, (Duke Health Systems)
Nalin Gupta, MD, Neurosurgeon, (UCSF)
Matthew Barkovich, MD, Neuroradiologist (UCSF)
Eileen Gutierrez, Tumor Board Coordinator (UCSF)
Why should a provider observe the DIPG DMG National Brain Tumor Board?
To know options to present to the patient for clinical trials, the status of those trials from people close to the trials, and protocols of compassionate care or treatment to consider outside of trials -- Consider this your think tank of solutions to offer from those who see DIPG DMG most often on what the next best steps might be within 12 weeks of diagnosis or 4 weeks following first progression.
To help place the patient on the radar of clinical trials enrolling across the country; to allow the patient family the opportunity to decide whether trial, compassionate protocol treatment or no treatment beyond standard of care is right for them
To learn from the tumor board -- what do those pediatric neuro oncologist who see many cases each year look for when evaluating newly diagnosed patients. What is most helpful in reviewing the MRI, results from biopsy, if any, and clinical presentation?
To network with providers who are exploring trial opportunities, and information to be gained from open access patient registries. Learn with others on the cutting edge of DIPG DMG about your patients and other patients like yours.
Why should a provider attend the DIPG DMG National Brain Tumor Board?
To know options to present to the patient for clinical trials, the status of those trials from people close to the trials, and protocols of compassionate care or treatment to consider outside of trials -- Consider this your think tank of solutions to offer from those who see DIPG DMG most often on what the next best steps might be within 12 weeks of diagnosis or 4 weeks following first progression.
To help place the patient on the radar of clinical trials enrolling across the country; to allow the patient family the opportunity to decide whether trial, compassionate protocol treatment or no treatment beyond standard of care is right for them.
To learn from the tumor board -- what do pediatric neuro oncologists, several who see more DIPG DMG cases than most, look for when evaluating newly diagnosed patients. What is most helpful in reviewing the MRI, results from biopsy, if any, and clinical presentation.
To network with providers who are exploring trial opportunities, and information to be gained from open access patient registries. Learn with others on the cutting edge of DIPG DMG about your patients and other patients like yours.
The DIPG DMG National Brain Tumor Board is funded by DDRFA
DDRFA is powered by families and foundations who know first-hand the journey of DIPG and DMG. Together, the members fund the DIPG DMG National Brain Tumor Board, basic and translational research, access to clinical trials and the use, integration and collection of patient derived data. Through DDRFA, our members work as fast as possible to fund and drive change because we are well aware lives depend on it. The DIPG DMG National Brain Tumor Board is also funded in part by the Elliot Rose Fund.
OUR MEMBERS
